---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-068615"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2026-06-01T12:30:30+00:00"
generated_at: "2026-06-01T12:35:29.880043+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Coherus Oncology annual meeting results: directors elected, equity plan approved, option repricing narrowly passes

## Summary
- Class III directors Dennis M. Lanfear and Mats L. Wahlström re-elected with 82.5M and 81.2M votes for each, respectively.
- Ratification of Ernst & Young as independent auditor approved by 121.1M votes for, 1.5M against.
- Say-on-pay advisory vote on executive compensation passed with 73.3M for, 10.9M against, 4.8M abstain.
- Stock option repricing proposal (Prop 4) approved in close vote: 46.0M for, 45.4M against, 0.4M abstain.
- Increase in shares reserved under Amended 2014 Equity Plan approved: 59.5M for, 24.9M against, 4.6M abstain.

## SEC filing metadata
- accession: 0001104659-26-068615
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2026-06-01T12:30:30+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465926068615/0001104659-26-068615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465926068615/chrs-20260527x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-068615
- JSON: https://secwatch.observer/filing/0001104659-26-068615.json
- Plain text: https://secwatch.observer/filing/0001104659-26-068615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.